SummarySecond harmonic generation (SHG)-based probes are useful for nonlinear optical imaging of biological structures, such as the plasma membrane. Several amphiphilic porphyrin-based dyes with high SHG coefficients have been synthesized with different hydrophilic head groups, and their cellular targeting has been studied. The probes with cationic head groups localize better at the plasma membrane than the neutral probes with zwitterionic or non-charged ethylene glycol-based head groups. Porphyrin dyes with only dications as hydrophilic head groups localize inside HEK293T cells to give SHG, whereas tricationic dyes localize robustly at the plasma membrane of cells, including neurons, in vitro and ex vivo. The copper(II) complex of the tricationic dye with negligible fluorescence quantum yield works as an SHG-only dye. The free-base tricationic dye has been demonstrated for two-photon fluorescence and SHG-based multimodal imaging. This study demonstrates the importance of a balance between the hydrophobicity and hydrophilicity of amphiphilic dyes for effective plasma membrane localization.

Pyropheophorbide-a methyl ester (PPa-OMe) has been modified by attaching electron-donor and -acceptor groups to alter its linear and nonlinear optical properties. Regioselective bromination of the terminal vinyl position and Suzuki coupling were used to attach a 4-(N,N-diethylaminophenyl) electron-donor group. The electron-acceptor dicyanomethylene was attached at the cyclic ketone position through a Knoevenagel condensation. Four different derivatives of PPa-OMe, containing either electron-donor or electron-acceptor groups, or both, were converted to hydrophilic bis-TEG amides to generate a series of amphiphilic dyes. The absorption and emission properties of all the dyes were compared to a previously reported push-pull type porphyrin-based dye and a commercial push-pull styryl dye, FM4-64. Electrochemical measurements reveal that the electron donor group causes a greater decrease in HOMO-LUMO gap than the electron-acceptor. TD-DFT calculations on optimized geometries (DFT) of all four dyes show that the HOMO is mostly localized on the donor, 4-(N,N-diethylaminophenyl), while the LUMO is distributed around the chlorin ring and the electron-acceptor. Hyper-Rayleigh scattering experiments show that the first-order hyperpolarizabilities of the dyes increase on attaching either electron-donor or -acceptor groups, having the highest value when both the donor and acceptor groups are attached. Two-photon excited fluorescence (TPEF) and second harmonic generation (SHG) images of the bis-TEG amide attached dyes in lipid monolayer-coated droplets of water-in-oil reveal that the TPEF and SHG involve transition dipole moments in different orientations.

No abstract

No abstract

Long-duration in vivo simultaneous imaging of multiple anatomical structures is useful for understanding physiological aspects of diseases, informative for molecular optimization in preclinical models, and has potential applications in surgical settings to improve clinical outcomes.Previous studies involving simultaneous imaging of multiple anatomical structures, e.g., blood and lymphatic vessels as well as peripheral nerves and sebaceous glands, have used genetically engineered mice, which require expensive and time-consuming methods. Here, an IgG4 isotype control antibody is labeled with a near-infrared dye and injected into a mouse ear to enable simultaneous visualization of blood and lymphatic vessels, peripheral nerves, and sebaceous glands for up to 3 hours using photoacoustic microscopy. For multiple anatomical structure imaging, peripheral nerves and sebaceous glands are imaged inside the injected dye-labeled antibody mass while the lymphatic vessels are visualized outside the mass. The efficacy of the contrast agent to label and localize deep medial lymphatic vessels and lymph nodes using photoacoustic computed tomography is demonstrated. The capability of a single injectable contrast agent to image multiple structures for several hours will potentially improve preclinical therapeutic optimization, shorten discovery timelines, and enable clinical treatments.